Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;10(5):497-511.
doi: 10.1016/S2213-2600(21)00506-3. Epub 2022 Apr 12.

Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment

Affiliations
Review

Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment

Ian A Yang et al. Lancet Respir Med. 2022 May.

Abstract

Chronic obstructive pulmonary disease (COPD) was traditionally thought to be caused by tobacco smoking. However, recognition of the importance of non-smoking-related risk factors for COPD has increased over the past decade, with evidence on the burden, risk factors, and clinical presentations of COPD in never-smokers. About half of all COPD cases worldwide are due to non-tobacco-related risk factors, which vary by geographical region. These factors include air pollution, occupational exposures, poorly controlled asthma, environmental tobacco smoke, infectious diseases, and low socioeconomic status. Impaired lung growth during childhood, caused by a range of early-life exposures, is associated with an increased risk of COPD. Potential mechanisms for the pathogenesis of COPD in never-smokers include inflammation, oxidative stress, airway remodelling, and accelerated lung ageing. Compared with smokers who develop COPD, never-smokers with COPD have relatively mild chronic respiratory symptoms, little or no emphysema, milder airflow limitation, and fewer comorbidities; however, exacerbations can still be frequent. Further research-including epidemiological, translational, clinical, and implementation studies-is needed to address gaps in understanding and to advance potential solutions to reduce the burden of COPD in never-smokers.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests IAY is a co-chair (unpaid) of the COPD-X Guidelines Committee of Lung Foundation Australia. CRJ reports receiving a grant to undertake an investigator-initiated clinical trial paid to her institution from GSK; consultancy fees from Novartis and AstraZeneca; honoraria for the development of educational materials from Boehringer Ingelheim, Novartis, and AstraZeneca; speaker's fees from Boehringer Ingelheim, Novartis, AstraZeneca, Cipla, and GSK; payment for expert testimony from Novartis and Chiesi; travel reimbursement from GSK, AstraZeneca, and Novartis; payment for advisory board membership and attendance at meetings from GSK, AstraZeneca, and Novartis; payment for attendance at meetings as a member of the National Dust Diseases Taskforce; and is chair (unpaid) of the board of Lung Foundation Australia and director (unpaid) of the Asbestos Diseases Research Institute. SSS is a member (unpaid) of the Board of Directors of the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

Comment in

MeSH terms